Logo
EnglishCookie löschen - von nun an wird die Spracheinstellung Ihres Browsers verwendet.
Bergmann, Lothar; Goebell, Peter J.; Kube, Ulrich; Kindler, Manfred; Herrmann, Edwin; Janssen, Jan; Schmitz, Joerg; Weikert, Steffen; Steiner, Gabriel; Jakob, Andreas; Staehler, Michael D.; Steiner, Thomas; Overkamp, Friedrich; Albrecht, Michael; Guderian, Gernot; Doehn, Christian (2013): Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study. In: Onkologie, Nr. 3: S. 95-100
[img]
Vorschau

PDF

441kB

Abstract

Background: Everolimus is approved for treatment of anti-vascularendothelial growth factor (VEGF)-refractory patients with metastaticrenal cell carcinoma (mRCC). Clinical trials rarely mirror treatmentreality. Thus, a broader evaluation of everolimus is valuable forroutine use. Patients and Methods: A German multicenternon-interventional study documented mRCC patients starting everolimusafter failure of initial VEGF-targeted therapy. Primary endpoint waseffectiveness, defined as time to progression (TIP) according toinvestigator assessment (time from first dose to progression). Results:Of 382 documented patients, 196 were included in this interim analysis.